Chemical metabolic inhibitors for the treatment of blood-borne cancers

Anti-Cancer Agents in Medicinal Chemistry

Volumn 14, Issue 2, 2014, Pages 223-232

  Villalba, Martin ^a,b   Lopez Royuela, Nuria ^a,c   Krzywinska, Ewelina ^a,c   Rathore, Moeez G ^a,c   Hipskind, Robert A ^c,d   Haouas, Houda ^b,c   Allende Vega, Nerea ^a,c  

^a INSERM   (France)

^b MONTPELLIER UNIVERSITY HOSPITAL   (France)

^c UNIVERSITY OF CARTHAGE   (Tunisia)

^d INSTITUT DE GÉNÉTIQUE MOLÉCULAIRE DE MONTPELLIER   (France)

Author keywords

Cancer immunosurveillance; DCA; Glutamine; Metformin; MHC I; OXPHOS; Warburg effect

Indexed keywords

ANIMALS; ANTINEOPLASTIC AGENTS; CELL TRANSPLANTATION; COMBINED MODALITY THERAPY; GLUTAMINE; GLYCOLYSIS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTONE DEACETYLASES; HUMANS; IMMUNOMODULATION; KILLER CELLS, NATURAL; LEUKEMIA; OXIDATIVE PHOSPHORYLATION; SIRTUINS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84893450338     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/18715206113136660374     Document Type: Article

References (119)

1. Dunn, G. P.; Bruce, A. T.; Ikeda, H.; Old, L. J.; Schreiber, R. D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol., 2002, 3 (11), 991-998.
2. Dunn, G. P.; Koebel, C. M.; Schreiber, R. D. Interferons, immunity and cancer immunoediting. Nat. Rev. Immunol., 2006, 6 (11), 836-848.
3. Cheong, H.; Lu, C.; Lindsten, T.; Thompson, C. B. Therapeutic targets in cancer cell metabolism and autophagy. Nat. Biotechnol., 2012, 30 (7), 671-678.
4. Kastritis, E.; Zervas, K.; Symeonidis, A.; Terpos, E.; Delimbassi, S.; Anagnostopoulos, N.; Michali, E.; Zomas, A.; Katodritou, E.; Gika, D.; Pouli, A.; Christoulas, D.; Roussou, M.; Kartasis, Z.; Economopoulos, T.; Dimopoulos, M. A. Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): An analysis of the Greek Myeloma Study Group (GMSG). Leukemia, 2009, 23 (6), 1152-1157.
5. Van de Donk, N. W.; Kamps, S.; Mutis, T.; Lokhorst, H. M. Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma. Leukemia, 2012, 26 (2), 199-213.
6. Alatrash, G.; Molldrem, J. J. Vaccines as consolidation therapy for myeloid leukemia. Exp. Rev. Hematol., 2011, 4 (1), 37-50.
7. Rubnitz, J. E.; Inaba, H.; Ribeiro, R. C.; Pounds, S.; Rooney, B.; Bell, T.; Pui, C. H.; Leung, W. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J. Clin. Oncol., 2010, 28 (6), 955-959.
8. Villalba, M.; Rathore, M. G.; Lopez-Royuela, N.; Krzywinska, E.; Garaude, J.; Allende-Vega, N. From tumor cell metabolism to tumor immune escape. Int. J. Biochem. Cell Biol., 2013, 45 (1), 106-113.
9. Warburg, O. On respiratory impairment in cancer cells. Science, 1956, 124 (3215), 269-270.
10. Li, T.; Kon, N.; Jiang, L.; Tan, M.; Ludwig, T.; Zhao, Y.; Baer, R.; Gu, W. Tumor suppression in the absence of p53-mediated cellcycle arrest, apoptosis, and senescence. Cell, 2012, 149 (6), 1269-1283.
11. Li, L.; Li, M.; Sun, C.; Francisco, L.; Chakraborty, S.; Sabado, M.; McDonald, T.; Gyorffy, J.; Chang, K.; Wang, S.; Fan, W.; Li, J.; Zhao, L. P.; Radich, J.; Forman, S.; Bhatia, S.; Bhatia, R. Altered hematopoietic cell gene expression precedes development of therapy-related myelodysplasia/acute myeloid leukemia and identifies patients at risk. Cancer Cell, 2011, 20 (5), 591-605.
12. Yusuf, R. Z.; Wang, Y. H.; Scadden, D. T. The secrets of the bone marrow niche: Metabolic priming for AML. Nat. Med., 2012, 18 (6), 865-867.
13. Mardis, E. R.; Ding, L.; Dooling, D. J.; Larson, D. E.; McLellan, M. D.; Chen, K.; Koboldt, D. C.; Fulton, R. S.; Delehaunty, K. D.; McGrath, S. D.; Fulton, L. A.; Locke, D. P.; Magrini, V. J.; Abbott, R. M.; Vickery, T. L.; Reed, J. S.; Robinson, J. S.; Wylie, T.; Smith, S. M.; Carmichael, L.; Eldred, J. M.; Harris, C. C.; Walker, J.; Peck, J. B.; Du, F.; Dukes, A. F.; Sanderson, G. E.; Brummett, A. M.; Clark, E.; McMichael, J. F.; Meyer, R. J.; Schindler, J. K.; Pohl, C. S.; Wallis, J. W.; Shi, X.; Lin, L.; Schmidt, H.; Tang, Y.; Haipek, C.; Wiechert, M. E.; Ivy, J. V.; Kalicki, J.; Elliott, G.; Ries, R. E.; Payton, J. E.; Westervelt, P.; Tomasson, M. H.; Watson, M. A.; Baty, J.; Heath, S.; Shannon, W. D.; Nagarajan, R.; Link, D. C.; Walter, M. J.; Graubert, T. A.; DiPersio, J. F.; Wilson, R. K.; Ley, T. J. Recurring mutations found by sequencing an acute myeloid leukemia genome. N. Engl. J. Med., 2009, 361 (11), 1058-1066.
14. Samudio, I.; Fiegl, M.; Andreeff, M. Mitochondrial uncoupling and the Warburg effect: molecular basis for the reprogramming of cancer cell metabolism. Cancer Res., 2009, 69 (6), 2163-2166.
15. Hitosugi, T.; Kang, S.; Vander Heiden, M. G.; Chung, T. W.; Elf, S.; Lythgoe, K.; Dong, S.; Lonial, S.; Wang, X.; Chen, G. Z.; Xie, J.; Gu, T. L.; Polakiewicz, R. D.; Roesel, J. L.; Boggon, T. J.; Khuri, F. R.; Gilliland, D. G.; Cantley, L. C.; Kaufman, J.; Chen, J. Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci. Signal, 2009, 2 (97), ra73.
16. Wang, Y.; Liu, Y.; Malek, S. N.; Zheng, P. Targeting HIF1alpha eliminates cancer stem cells in hematological malignancies. Cell Stem Cell, 2011, 8 (4), 399-411.
17. Villalba, M.; Rathore, M. G.; Lopez-Royuela, N.; Krzywinska, E.; Garaude, J.; Allende-Vega, N. From tumor cell metabolism to tumor immune escape. Int. J. Biochem. Cell Biol., 2012.
18. Samudio, I.; Harmancey, R.; Fiegl, M.; Kantarjian, H.; Konopleva, M.; Korchin, B.; Kaluarachchi, K.; Bornmann, W.; Duvvuri, S.; Taegtmeyer, H.; Andreeff, M. Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J. Clin. Invest., 2010, 120 (1), 142-156.
19. Tirado-Velez, J. M.; Joumady, I.; Saez-Benito, A.; Cozar-Castellano, I.; Perdomo, G. Inhibition of fatty acid metabolism reduces human myeloma cells proliferation. PLoS One, 2012, 7 (9), e46484.
20. Carr, E. L.; Kelman, A.; Wu, G. S.; Gopaul, R.; Senkevitch, E.; Aghvanyan, A.; Turay, A. M.; Frauwirth, K. A. Glutamine uptake and metabolism are coordinately regulated by ERK/MAPK during T lymphocyte activation. J. Immunol., 2010, 185 (2), 1037-1044.
21. Rathore, M. G.; Saumet, A.; Rossi, J. F.; De Bettignies, C.; Tempe, D.; Lecellier, C. H.; Villalba, M. The NF-kappaB member p65 controls glutamine metabolism through miR-23a. Int. J. Biochem. Cell Biol., 2012, 44 (9), 1448-1456.
22. Karin, M.; Greten, F. R. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat. Rev. Immunol., 2005, 5 (10), 749-759.
23. Espinosa, L.; Cathelin, S.; D'Altri, T.; Trimarchi, T.; Statnikov, A.; Guiu, J.; Rodilla, V.; Ingles-Esteve, J.; Nomdedeu, J.; Bellosillo, B.; Besses, C.; Abdel-Wahab, O.; Kucine, N.; Sun, S. C.; Song, G.; Mullighan, C. C.; Levine, R. L.; Rajewsky, K.; Aifantis, I.; Bigas, A. The Notch/Hes1 pathway sustains NF-kappaB activation through CYLD repression in T cell leukemia. Cancer Cell, 2010, 18 (3), 268-281.
24. Zhao, W. L. Targeted therapy in T-cell malignancies: dysregulation of the cellular signaling pathways. Leukemia, 2010, 24 (1), 13-21.
25. Dang, C. V. MYC, microRNAs and glutamine addiction in cancers. Cell Cycle, 2009, 8 (20), 3243-3245.
26. Shanware, N. P.; Mullen, A. R.; De Berardinis, R. J.; Abraham, R. T. Glutamine: pleiotropic roles in tumor growth and stress resistance. J. Mol. Med., 2011, 89 (3), 229-236.
27. Gaglio, D.; Soldati, C.; Vanoni, M.; Alberghina, L.; Chiaradonna, F. Glutamine deprivation induces abortive s-phase rescued by deoxyribonucleotides in k-ras transformed fibroblasts. PLoS One, 2009, 4 (3), e4715.
28. Duran, R. V.; Oppliger, W.; Robitaille, A. M.; Heiserich, L.; Skendaj, R.; Gottlieb, E.; Hall, M. N. Glutaminolysis activates RagmTORC1 signaling. Mol. Cell, 2012, 47 (3), 349-358.
29. Rossignol, R.; Gilkerson, R.; Aggeler, R.; Yamagata, K.; Remington, S. J.; Capaldi, R. A. Energy substrate modulates mitochondrial structure and oxidative capacity in cancer cells. Cancer Res., 2004, 64 (3), 985-993.
30. Wise, D. R.; DeBerardinis, R. J.; Mancuso, A.; Sayed, N.; Zhang, X. Y.; Pfeiffer, H. K.; Nissim, I.; Daikhin, E.; Yudkoff, M.; McMahon, S. B.; Thompson, C. B. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc. Natl. Acad. Sci. USA, 2008, 105 (48), 18782-18787.
31. Charni, S.; De Bettignies, G.; Rathore, M. G.; Aguilo, J. I.; van den Elsen, P. J.; Haouzi, D.; Hipskind, R. A.; Enriquez, J. A.; Sanchez-Beato, M.; Pardo, J.; Anel, A.; Villalba, M. Oxidative phosphorylation induces de novo expression of the MHC class I in tumor cells through the ERK5 pathway. J. Immunol., 2010, 185 (6), 3498-3503.
32. Wang, J. B.; Erickson, J. W.; Fuji, R.; Ramachandran, S.; Gao, P.; Dinavahi, R.; Wilson, K. F.; Ambrosio, A. L.; Dias, S. M.; Dang, C. V.; Cerione, R. A. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell, 2010, 18 (3), 207-219.
33. Hu, W.; Zhang, C.; Wu, R.; Sun, Y.; Levine, A.; Feng, Z. Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. Proc. Natl. Acad. Sci. USA, 2010, 107 (16), 7455-7460.
34. Suzuki, S.; Tanaka, T.; Poyurovsky, M. V.; Nagano, H.; Mayama, T.; Ohkubo, S.; Lokshin, M.; Hosokawa, H.; Nakayama, T.; Suzuki, Y.; Sugano, S.; Sato, E.; Nagao, T.; Yokote, K.; Tatsuno, I.; Prives, C. Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species. Proc. Natl. Acad. Sci. USA, 2010, 107 (16), 7461-7466.
35. Wise, D. R.; Thompson, C. B. Glutamine addiction: a new therapeutic target in cancer. Trends Biochem. Sci., 2010, 35 (8), 427-433.
36. Narta, U. K.; Kanwar, S. S.; Azmi, W. Pharmacological and clinical evaluation of L-asparaginase in the treatment of leukemia. Crit. Rev. Oncol/Hematol., 2007, 61 (3), 208-221.
37. Avramis, V. I.; Panosyan, E. H. Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future. Clin. Pharmacokinetics, 2005, 44 (4), 367-393.
38. Wu, M. C.; Arimura, G. K.; Yunis, A. A. Mechanism of sensitivity of cultured pancreatic carcinoma to asparaginase. Int. J. Cancer, 1978, 22 (6), 728-733.
39. Robinson, M. M.; McBryant, S. J.; Tsukamoto, T.; Rojas, C.; Ferraris, D. V.; Hamilton, S. K.; Hansen, J. C.; Curthoys, N. P. Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylacetamido-1, 2, 4-thiadiazol-2-yl)ethyl sulfide (BPTES). Biochem. J., 2007, 406 (3), 407-414.
40. Le, A.; Lane, A. N.; Hamaker, M.; Bose, S.; Gouw, A.; Barbi, J.; Tsukamoto, T.; Rojas, C. J.; Slusher, B. S.; Zhang, H.; Zimmerman, L. J.; Liebler, D. C.; Slebos, R. J.; Lorkiewicz, P. K.; Higashi, R. M.; Fan, T. W.; Dang, C. V. Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab., 2012, 15 (1), 110-121.
41. Yang, C.; Sudderth, J.; Dang, T.; Bachoo, R. M.; McDonald, J. G.; DeBerardinis, R. J. Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose metabolism or Akt signaling. Cancer Res., 2009, 69 (20), 7986-7993.
42. Mereles, D.; Hunstein, W. Epigallocatechin-3-gallate (EGCG) for Clinical Trials: More Pitfalls than Promises? Int. J. Mol. Sci., 2011, 12 (9), 5592-5603.
43. Stacpoole, P. W.; Gilbert, L. R.; Neiberger, R. E.; Carney, P. R.; Valenstein, E.; Theriaque, D. W.; Shuster, J. J. Evaluation of longterm treatment of children with congenital lactic acidosis with dichloroacetate. Pediatrics, 2008, 121 (5), e1223-1228.
44. Michelakis, E. D.; Sutendra, G.; Dromparis, P.; Webster, L.; Haromy, A.; Niven, E.; Maguire, C.; Gammer, T. L.; Mackey, J. R.; Fulton, D.; Abdulkarim, B.; McMurtry, M. S.; Petruk, K. C. Metabolic modulation of glioblastoma with dichloroacetate. Sci. Transl. Med., 2010, 2 (31), 31ra34.
45. Flavin, D. F. Non-Hodgkin's Lymphoma Reversal with Dichloroacetate. J. Oncol., 2010, 2010, 4.
46. Zhang, N.; Palmer, A. F. Development of a dichloroacetic acidhemoglobin conjugate as a potential targeted anti-cancer therapeutic. Biotechnol. Bioengineer., 2011, 108 (6), 1413-1420.
47. Luo, Z.; Zang, M.; Guo, W. AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. Future Oncol., 2010, 6 (3), 457-470.
48. Jeon, S. M.; Chandel, N. S.; Hay, N. AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature, 2012, 485 (7400), 661-665.
49. Liu, L.; Ulbrich, J.; Muller, J.; Wustefeld, T.; Aeberhard, L.; Kress, T. R.; Muthalagu, N.; Rycak, L.; Rudalska, R.; Moll, R.; Kempa, S.; Zender, L.; Eilers, M.; Murphy, D. J. Deregulated MYC expression induces dependence upon AMPK-related kinase 5. Nature, 2012, 483 (7391), 608-612.
50. Alessi, D. R.; Sakamoto, K.; Bayascas, J. R. LKB1-dependent signaling pathways. Annu. Rev. Biochem., 2006, 75, 137-163.
51. Blagih, J.; Krawczyk, C. M.; Jones, R. G. LKB1 and AMPK: central regulators of lymphocyte metabolism and function. Immunol. Rev., 2012, 249 (1), 59-71.
52. Faubert, B.; Boily, G.; Izreig, S.; Griss, T.; Samborska, B.; Dong, Z.; Dupuy, F.; Chambers, C.; Fuerth, B. J.; Viollet, B.; Mamer, O. A.; Avizonis, D.; DeBerardinis, R. J.; Siegel, P. M.; Jones, R. G. AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. Cell Metab., 2013, 17 (1), 113-124.
53. Martelli, A. M.; Chiarini, F.; Evangelisti, C.; Ognibene, A.; Bressanin, D.; Billi, A. M.; Manzoli, L.; Cappellini, A.; McCubrey, J. A. Targeting the liver kinase B1/AMP-activated protein kinase pathway as a therapeutic strategy for hematological malignancies. Exp. Opin. Therapeutic Targets, 2012, 16 (7), 729-742.
54. Buzzai, M.; Jones, R. G.; Amaravadi, R. K.; Lum, J. J.; DeBerardinis, R. J.; Zhao, F.; Viollet, B.; Thompson, C. B. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res., 2007, 67 (14), 6745-6752.
55. Huang, X.; Wullschleger, S.; Shpiro, N.; McGuire, V. A.; Sakamoto, K.; Woods, Y. L.; McBurnie, W.; Fleming, S.; Alessi, D. R. Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem. J., 2008, 412 (2), 211-221.
56. Weiser, M. A.; Cabanillas, M. E.; Konopleva, M.; Thomas, D. A.; Pierce, S. A.; Escalante, C. P.; Kantarjian, H. M.; O'Brien, S. M. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen. Cancer, 2004, 100 (6), 1179-1185.
57. Grimaldi, C.; Chiarini, F.; Tabellini, G.; Ricci, F.; Tazzari, P. L.; Battistelli, M.; Falcieri, E.; Bortul, R.; Melchionda, F.; Iacobucci, I.; Pagliaro, P.; Martinelli, G.; Pession, A.; Barata, J. T.; McCubrey, J. A.; Martelli, A. M. AMP-dependent kinase/mammalian target of rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: therapeutic implications. Leukemia, 2012, 26 (1), 91-100.
58. Pan, J.; Chen, C.; Jin, Y.; Fuentes-Mattei, E.; Velazquez-Tores, G.; Benito, J. M.; Konopleva, M.; Andreeff, M.; Lee, M. H.; Yeung, S. C. Differential impact of structurally different anti-diabetic drugs on proliferation and chemosensitivity of acute lymphoblastic leukemia cells. Cell Cycle, 2012, 11 (12), 2314-2326.
59. Vakana, E.; Altman, J. K.; Glaser, H.; Donato, N. J.; Platanias, L. C. Antileukemic effects of AMPK activators on BCR-ABL-expressing cells. Blood, 2011, 118 (24), 6399-6402.
60. Green, A. S.; Chapuis, N.; Maciel, T. T.; Willems, L.; Lambert, M.; Arnoult, C.; Boyer, O.; Bardet, V.; Park, S.; Foretz, M.; Viollet, B.; Ifrah, N.; Dreyfus, F.; Hermine, O.; Moura, I. C.; Lacombe, C.; Mayeux, P.; Bouscary, D.; Tamburini, J. The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation. Blood, 2010, 116 (20), 4262-4273.
61. Viollet, B.; Guigas, B.; Sanz Garcia, N.; Leclerc, J.; Foretz, M.; Andreelli, F. Cellular and molecular mechanisms of metformin: an overview. Clin. Sci., 2012, 122 (6), 253-270.
62. Feng, Z.; Hu, W.; de Stanchina, E.; Teresky, A. K.; Jin, S.; Lowe, S.; Levine, A. J. The regulation of AMPK beta1, TSC2, and PTEN expression by p53: stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways. Cancer Res., 2007, 67 (7), 3043-3053.
63. Gottlieb, E.; Vousden, K. H. P53 regulation of metabolic pathways. Cold Spring Harbor Perspectives Biol., 2010, 2 (4), a001040.
64. Puzio-Kuter, A. M. The Role of P53 in metabolic regulation. Genes & Cancer, 2011, 2 (4), 385-391.
65. Nigro, J. M.; Baker, S. J.; Preisinger, A. C.; Jessup, J. M.; Hostetter, R.; Cleary, K.; Bigner, S. H.; Davidson, N.; Baylin, S.; Devilee, P.; Glover, T.; Collins, F. S.; Weston, A.; Modali, R.; Harris, C. C.; Vogelstein, B. Mutations in the p53 gene occur in diverse human tumour types. Nature, 1989, 342 (6250), 705-708.
66. Imamura, J.; Miyoshi, I.; Koeffler, H. P. P53 in hematologic malignancies. Blood, 1994, 84 (8), 2412-2421.
67. Malcikova, J.; Smardova, J.; Rocnova, L.; Tichy, B.; Kuglik, P.; Vranova, V.; Cejkova, S.; Svitakova, M.; Skuhrova Francova, H.; Brychtova, Y.; Doubek, M.; Brejcha, M.; Klabusay, M.; Mayer, J.; Pospisilova, S.; Trbusek, M. Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage. Blood, 2009, 114 (26), 5307-5314.
68. Brown, C. J.; Cheok, C. F.; Verma, C. S.; Lane, D. P. Reactivation of p53: from peptides to small molecules. Trends Pharmacol. Sci., 2011, 32 (1), 53-62.
69. Peng, Y.; Li, C.; Chen, L.; Sebti, S.; Chen, J. Rescue of mutant p53 transcription function by ellipticine. Oncogene, 2003, 22 (29), 4478-4487.
70. Nahi, H.; Merup, M.; Lehmann, S.; Bengtzen, S.; Mollgard, L.; Selivanova, G.; Wiman, K. G.; Paul, C. PRIMA-1 induces apoptosis in acute myeloid leukaemia cells with p53 gene deletion. Br. J. Haematol., 2006, 132 (2), 230-236.
71. Wang, F.; Liu, J.; Robbins, D.; Morris, K.; Sit, A.; Liu, Y. Y.; Zhao, Y. Mutant p53 exhibits trivial effects on mitochondrial functions which can be reactivated by ellipticine in lymphoma cells. Apoptosis: An. Int. J. Programmed Cell Death, 2011, 16 (3), 301-310.
72. Li, D.; Marchenko, N. D.; Schulz, R.; Fischer, V.; Velasco-Hernandez, T.; Talos, F.; Moll, U. M. Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells. Mol. Cancer Res., 2011, 9 (5), 577-588.
73. Lane, A. A.; Chabner, B. A. Histone deacetylase inhibitors in cancer therapy. J. Clin. Oncol., 2009, 27 (32), 5459-5468.
74. Minucci, S.; Pelicci, P. G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer, 2006, 6 (1), 38-51.
75. Mitsiades, C. S.; Mitsiades, N. S.; McMullan, C. J.; Poulaki, V.; Shringarpure, R.; Hideshima, T.; Akiyama, M.; Chauhan, D.; Munshi, N.; Gu, X.; Bailey, C.; Joseph, M.; Libermann, T. A.; Richon, V. M.; Marks, P. A.; Anderson, K. C. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc. Natl. Acad. Sci. USA, 2004, 101 (2), 540-545.
76. Balasubramanian, S.; Ramos, J.; Luo, W.; Sirisawad, M.; Verner, E.; Buggy, J. J. A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia, 2008, 22 (5), 1026-1034.
77. Mwakwari, S. C.; Guerrant, W.; Patil, V.; Khan, S. I.; Tekwani, B. L.; Gurard-Levin, Z. A.; Mrksich, M.; Oyelere, A. K. Non-peptide macrocyclic histone deacetylase inhibitors derived from tricyclic ketolide skeleton. J. Med. Chem., 2010, 53 (16), 6100-6111.
78. Suzuki, T.; Ota, Y.; Ri, M.; Bando, M.; Gotoh, A.; Itoh, Y.; Tsumoto, H.; Tatum, P. R.; Mizukami, T.; Nakagawa, H.; Iida, S.; Ueda, R.; Shirahige, K.; Miyata, N. Rapid discovery of highly potent and selective inhibitors of histone deacetylase 8 using click chemistry to generate candidate libraries. J Med. Chem., 2012, 55 (22), 9562-9575.
79. Liu, T.; Liu, P. Y.; Marshall, G. M. The critical role of the class III histone deacetylase SIRT1 in cancer. Cancer Res., 2009, 69 (5), 1702-1705.
80. Sugden, M. C.; Caton, P. W.; Holness, M. J. PPAR control: it's SIRTainly as easy as PGC. J. Endocrinol., 2010, 204 (2), 93-104.
81. Venugopal, R.; Jaiswal, A. K. Nrf2 and Nrf1 in association with Jun proteins regulate antioxidant response element-mediated expression and coordinated induction of genes encoding detoxifying enzymes. Oncogene, 1998, 17 (24), 3145-3156.
82. Li, X.; Kazgan, N. Mammalian sirtuins and energy metabolism. Int. J. Biol. Sci., 2011, 7 (5), 575-587.
83. Audrito, V.; Vaisitti, T.; Rossi, D.; Gottardi, D.; D'Arena, G.; Laurenti, L.; Gaidano, G.; Malavasi, F.; Deaglio, S. Nicotinamide blocks proliferation and induces apoptosis of chronic lymphocytic leukemia cells through activation of the p53/miR-34a/SIRT1 tumor suppressor network. Cancer Res., 2011, 71 (13), 4473-4483.
84. Bradbury, C. A.; Khanim, F. L.; Hayden, R.; Bunce, C. M.; White, D. A.; Drayson, M. T.; Craddock, C.; Turner, B. M. Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia, 2005, 19 (10), 1751-1759.
85. Li, L.; Wang, L.; Wang, Z.; Ho, Y.; McDonald, T.; Holyoake, T. L.; Chen, W.; Bhatia, R. Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell, 2012, 21 (2), 266-281.
86. Chung, S.; Yao, H.; Caito, S.; Hwang, J. W.; Arunachalam, G.; Rahman, I. Regulation of SIRT1 in cellular functions: role of polyphenols. Arch Biochem Biophys, 2010, 501 (1), 79-90.
87. Li, K.; Luo, J. The role of SIRT1 in tumorigenesis. N. Am. J. Med. Sci. (Boston), 2011, 4 (2), 104-106.
88. Lain, S.; Hollick, J. J.; Campbell, J.; Staples, O. D.; Higgins, M.; Aoubala, M.; McCarthy, A.; Appleyard, V.; Murray, K. E.; Baker, L.; Thompson, A.; Mathers, J.; Holland, S. J.; Stark, M. J.; Pass, G.; Woods, J.; Lane, D. P.; Westwood, N. J. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell, 2008, 13 (5), 454-463.
89. Lara, E.; Mai, A.; Calvanese, V.; Altucci, L.; Lopez-Nieva, P.; Martinez-Chantar, M. L.; Varela-Rey, M.; Rotili, D.; Nebbioso, A.; Ropero, S.; Montoya, G.; Oyarzabal, J.; Velasco, S.; Serrano, M.; Witt, M.; Villar-Garea, A.; Imhof, A.; Mato, J. M.; Esteller, M.; Fraga, M. F. Salermide, a Sirtuin inhibitor with a strong cancerspecific proapoptotic effect. Oncogene, 2009, 28 (6), 781-791.
90. Rotili, D.; Tarantino, D.; Nebbioso, A.; Paolini, C.; Huidobro, C.; Lara, E.; Mellini, P.; Lenoci, A.; Pezzi, R.; Botta, G.; Lahtela-Kakkonen, M.; Poso, A.; Steinkuhler, C.; Gallinari, P.; De Maria, R.; Fraga, M.; Esteller, M.; Altucci, L.; Mai, A. Discovery of salermide-related sirtuin inhibitors: binding mode studies and antiproliferative effects in cancer cells including cancer stem cells. J. Med. Chem., 2012, 55 (24), 10937-10947.
91. Price, N. L.; Gomes, A. P.; Ling, A. J.; Duarte, F. V.; Martin-Montalvo, A.; North, B. J.; Agarwal, B.; Ye, L.; Ramadori, G.; Teodoro, J. S.; Hubbard, B. P.; Varela, A. T.; Davis, J. G.; Varamini, B.; Hafner, A.; Moaddel, R.; Rolo, A. P.; Coppari, R.; Palmeira, C. M.; de Cabo, R.; Baur, J. A.; Sinclair, D. A. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab., 2012, 15 (5), 675-690.
92. Roman, V.; Billard, C.; Kern, C.; Ferry-Dumazet, H.; Izard, J. C.; Mohammad, R.; Mossalayi, D. M.; Kolb, J. P. Analysis of resveratrol-induced apoptosis in human B-cell chronic leukaemia. Br. J. Haematol., 2002, 117 (4), 842-851.
93. Cecchinato, V.; Chiaramonte, R.; Nizzardo, M.; Cristofaro, B.; Basile, A.; Sherbet, G. V.; Comi, P. Resveratrol-induced apoptosis in human T-cell acute lymphoblastic leukaemia MOLT-4 cells. Biochem. Pharmacol., 2007, 74 (11), 1568-1574.
94. Jezek, P.; Plecita-Hlavata, L.; Smolkova, K.; Rossignol, R. Distinctions and similarities of cell bioenergetics and the role of mitochondria in hypoxia, cancer, and embryonic development. Int. J. Biochem. Cell Biol., 2010, 42 (5), 604-622.
95. Bellance, N.; Lestienne, P.; Rossignol, R. Mitochondria: From bioenergetics to the metabolic regulation of carcinogenesis. Front. Biosci., 2009, 14, 4015-4034.
96. Smolkova, K.; Plecita-Hlavata, L.; Bellance, N.; Benard, G.; Rossignol, R.; Jezek, P. Waves of gene regulation suppress and then restore oxidative phosphorylation in cancer cells. Int. J. Biochem. Cell Biol., 2011, 43 (7), 950-968.
97. Burnet, F. M. The concept of immunological surveillance. Prog. Exp. Tumor. Res., 1970, 13, 1-27.
98. Garaude, J.; Kaminski, S.; Charni, S.; Aguilo, J. I.; Jacquet, C.; Plays, M.; Hernandez, J.; Rodriguez, F.; Hipskind, R. A.; Anel, A.; Villalba, M. Impaired anti-leukemic immune response in PKCthetadeficient mice. Mol. Immunol., 2008, 45 (12), 3463-3469.
99. Kaminski, S.; Adjali, O.; Jacquet, C.; Garaude, J.; Keriel, A.; Lassaux, A.; Hipskind, R.; Sitbon, M.; Taylor, N.; Villalba, M. The protooncogene Vav1 regulates murine leukemia virus-induced Tcell leukemogenesis. Oncoimmunology, 2012, 1 (5), 600-608.
100. Anel, A.; Aguilo, J. I.; Catalan, E.; Garaude, J.; Rathore, M. G.; Pardo, J.; Villalba, M. Protein Kinase c-theta (PKC-theta) in natural killer cell function and anti-tumor immunity. Front. Immunol., 2012, 3, 187.
101. Aguilo, J. I.; Garaude, J.; Pardo, J.; Villalba, M.; Anel, A. Protein kinase C-theta is required for NK cell activation and in vivo control of tumor progression. J. Immunol., 2009, 182 (4), 1972-1981.
102. Alcami, A.; Koszinowski, U. H. Viral mechanisms of immune evasion. Trends Microbiol., 2000, 8 (9), 410-418.
103. Aptsiauri, N.; Cabrera, T.; Garcia-Lora, A.; Lopez-Nevot, M. A.; Ruiz-Cabello, F.; Garrido, F. MHC class I antigens and immune surveillance in transformed cells. Int. Rev. Cytol., 2007, 256, 139-189.
104. Campoli, M.; Ferrone, S. HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. Oncogene, 2008, 27 (45), 5869-5885.
105. Vivier, E.; Tomasello, E.; Baratin, M.; Walzer, T.; Ugolini, S. Functions of natural killer cells. Nat. Immunol., 2008, 9 (5), 503-510.
106. Pan, B.; Lentzsch, S. The application and biology of immunomodulatory drugs (IMiDs) in cancer. Pharmacol. Therapeut., 2012, 136 (1), 56-68.
107. Latif, T.; Chauhan, N.; Khan, R.; Moran, A.; Usmani, S. Z. Thalidomide and its analogues in the treatment of multiple myeloma. Exp Hematol Oncol., 2012, 1 (1), 27.
108. Ito, T.; Ando, H.; Suzuki, T.; Ogura, T.; Hotta, K.; Imamura, Y.; Yamaguchi, Y.; Handa, H. Identification of a primary target of thalidomide teratogenicity. Science, 2010, 327 (5971), 1345-1350.
109. Zhu, Y. X.; Kortuem, K. M.; Stewart, A. K. Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leuk. Lymphoma, 2012.
110. Hayashi, T.; Hideshima, T.; Akiyama, M.; Podar, K.; Yasui, H.; Raje, N.; Kumar, S.; Chauhan, D.; Treon, S. P.; Richardson, P.; Anderson, K. C. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br. J. Haematol., 2005, 128 (2), 192-203.
111. Reitzer, L. J.; Wice, B. M.; Kennell, D. Evidence that glutamine, not sugar, is the major energy source for cultured HeLa cells. J. Biol. Chem., 1979, 254 (8), 2669-2676.
112. Oliveras-Ferraros, C.; Cufi, S.; Vazquez-Martin, A.; Menendez, O. J.; Bosch-Barrera, J.; Martin-Castillo, B.; Joven, J.; Menendez, J. A. Metformin rescues cell surface major histocompatibility complex class I (MHC-I) deficiency caused by oncogenic transformation. Cell Cycle, 2012, 11 (5), 865-870.
113. Charni, S.; Aguilo, J. I.; Garaude, J.; de Bettignies, G.; Jacquet, C.; Hipskind, R. A.; Singer, D.; Anel, A.; Villalba, M. ERK5 Knockdown generates mouse leukemia cells with low MHC class I levels that activate NK cells and block tumorigenesis. J. Immunol., 2009, 182 (6), 3398-3405.
114. Garaude, J.; Cherni, S.; Kaminski, S.; Delepine, E.; Chable-Bessia, C.; Benkirane, M.; Borges, J.; Pandiella, A.; Iniguez, M. A.; Fresno, M.; Hipskind, R. A.; Villalba, M. ERK5 activates NF-kappaB in leukemic T cells and is essential for their growth in vivo. J. Immunol., 2006, 177 (11), 7607-7617.
115. Garaude, J.; Kaminski, S.; Cherni, S.; Hipskind, R. A.; Villalba, M. The Role of ERK5 in T-Cell Signalling. Scand. J. Immunol., 2005, 62 (6), 515-520.
116. Alvarez-Fernandez, S.; Ortiz-Ruiz, M. J.; Parrott, T.; Zaknoen, S.; Ocio, E. M.; San Miguel, J.; Burrows, F. J.; Esparis-Ogando, A.; Pandiella, A. Potent Antimyeloma Activity of a Novel ERK5/CDK Inhibitor. Clin. Cancer Res., 2013, 19 (10), 2677-2687.
117. Galluzzi, L.; Vacchelli, E.; Eggermont, A.; Fridman, W. H.; Galon, J.; Sautes-Fridman, C.; Tartour, E.; Zitvogel, L.; Kroemer, G. Trial Watch: Adoptive cell transfer immunotherapy. Oncoimmunology, 2012, 1 (3), 306-315.
118. Ardolino, M.; Zingoni, A.; Cerboni, C.; Cecere, F.; Soriani, A.; Iannitto, M. L.; Santoni, A. DNAM-1 ligand expression on Agstimulated T lymphocytes is mediated by ROS-dependent activation of DNA-damage response: relevance for NK-T cell interaction. Blood, 2011, 117 (18), 4778-4786.
119. Wang, R.; Green, D. R. Metabolic checkpoints in activated T cells. Nat. Immunol., 2012, 13 (10), 907-915.